The antibody candidates were developed using Harbour's proprietary full-length human immunoglobulin G (IgG) molecules (H2L2) and heavy chain only human IgG molecules (HCAb) fully human transgenic mouse (Harbour Mice) platforms. One of the programs under the collaboration is an HBICE-bispecific antibody that was developed on Harbour's HBICE immune cell-engager platform.

Under the agreement, Hualan Genetic will be responsible for preclinical and process development of the programs in exchange for exclusive rights for the development, manufacturing, and commercialization of the antibody drugs in greater China (Mainland China, Hong Kong, Taiwan, and Macau). Harbour will retain rights for advancing the clinical development and commercialization in the rest of the world.

Both companies will collaborate on clinical development and drug manufacturing. Harbour will receive an upfront payment of $8.75 million and royalties based on sales in greater China.

Harbour BioMed, Vir to develop new therapies
Harbour Biomed and Vir Biotechnology have partnered to research and develop novel immuno-oncology and infectious disease therapies.

Companies work to develop combo mAb, NK cell COVID-19 therapy
A new research project is bringing together universities and pharmaceutical companies to collaborate on the development of a combination of a monoclonal...

AbbVie licenses antibody technology for COVID-19
AbbVie, Harbour BioMed, Utrecht University, and Erasmus Medical Center announced that they have entered into a collaboration to develop a novel antibody...

Researchers investigate how a potent mAb blocks SARS-CoV-2
Based on previous research that explored therapies against SARS-CoV, a new report has identified a fully human monoclonal antibody (mAb) that prevents...